Compare SCKT & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCKT | INDP |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 4.0M |
| IPO Year | 1995 | N/A |
| Metric | SCKT | INDP |
|---|---|---|
| Price | $1.06 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.9K | ★ 39.0K |
| Earning Date | 10-22-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,945,490.00 | N/A |
| Revenue This Year | $8.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $1.65 |
| 52 Week High | $1.72 | $47.60 |
| Indicator | SCKT | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 39.79 |
| Support Level | $1.24 | $2.39 |
| Resistance Level | $1.29 | $2.94 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 9.93 | 11.39 |
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the Americas, Europe, Asia Pacific, and Africa, of which the majority of the revenue is generated from the United States.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.